What rapid‑sequence intubation (RSI) medication dosing should be used for an adult patient with chronic kidney disease who is in cardiac arrest?

RSI Medication Approach for Cardiac Arrest Patients with CKD

In a patient with chronic kidney disease who is in cardiac arrest, omit sedative-hypnotic induction agents entirely and proceed directly with neuromuscular blockade alone, as the patient is already unconscious and hemodynamic preservation is irrelevant during active arrest.

Rationale for Medication Selection in Cardiac Arrest

Why No Induction Agent is Needed

The 2023 Society of Critical Care Medicine guidelines emphasize that sedative-hypnotic agents are administered during RSI specifically to induce unconsciousness before paralysis 1. However, a patient in cardiac arrest is already unconscious and lacks protective airway reflexes. The primary concern with induction agents—causing awareness during paralysis—is completely irrelevant in this clinical scenario.

Additionally:

• Hemodynamic effects are moot: All induction agents (etomidate, ketamine, propofol, midazolam) carry some risk of worsening hypotension or precipitating cardiac arrest in hemodynamically unstable patients 1
• During active cardiac arrest, the patient has no blood pressure to preserve, making the hemodynamic profile of any sedative agent irrelevant
• Time should not be wasted drawing up and administering medications that provide no clinical benefit

Neuromuscular Blockade Selection

Administer rocuronium 1.2 mg/kg or succinylcholine 1.5 mg/kg to facilitate optimal intubating conditions 1.

Choice between agents:

• Rocuronium is preferred in cardiac arrest if:

  • Hyperkalemia is suspected (common in CKD patients, especially with acute kidney injury superimposed on chronic disease)
  • Prolonged downtime suggests possible rhabdomyolysis
  • Recent burns, crush injuries, or denervation injuries are present

• Succinylcholine may be used if:

  • No contraindications exist
  • Faster onset is desired (though the difference is minimal with high-dose rocuronium)
  • Critical caveat: CKD patients often have baseline hyperkalemia; check recent potassium levels if available, and avoid succinylcholine if K+ >5.5 mEq/L or unknown

The 2023 SCCM guidelines suggest no significant difference between these agents for first-pass success when rocuronium is dosed appropriately 1.

CKD-Specific Considerations

Medication Dosing in Renal Failure

• Rocuronium: No dose adjustment needed for single RSI dose; renal elimination is minimal
• Succinylcholine: Standard dosing appropriate; however, hyperkalemia risk is the primary concern, not drug clearance
• Both agents can be given at standard RSI doses even in severe CKD or dialysis-dependent patients for a single intubation dose

Hyperkalemia Assessment

In cardiac arrest with CKD:

• If recent labs show K+ >5.5 mEq/L → use rocuronium
• If K+ unknown and patient has ESRD, missed dialysis, or ECG shows peaked T-waves → use rocuronium
• If arrest rhythm is PEA or asystole (more likely with severe hyperkalemia) → strongly favor rocuronium

Post-Intubation Management

Once return of spontaneous circulation (ROSC) is achieved:

• Immediately initiate sedation and analgesia to prevent awareness if rocuronium was used (longer duration of action) 1
• Consider involving pharmacy early to optimize post-intubation sedation protocols 1
• Standard post-cardiac arrest care per 2025 ILCOR guidelines 2

Common Pitfalls to Avoid

1. Do not delay intubation to administer unnecessary sedation in an unconscious, arrested patient
2. Do not use succinylcholine reflexively without considering hyperkalemia risk in CKD patients
3. Do not forget post-ROSC sedation if using rocuronium—the paralytic outlasts the arrest, and awareness during paralysis is a serious complication 1
4. Do not underdose rocuronium—use full 1.2 mg/kg for RSI conditions, not the lower intubating dose

Algorithm Summary

Cardiac Arrest + CKD Patient Requiring Intubation
↓
Patient unconscious? → YES (by definition in arrest)
↓
Skip induction agent entirely
↓
Check for hyperkalemia risk:
├─ K+ >5.5, ESRD, missed dialysis, peaked T-waves → Rocuronium 1.2 mg/kg
└─ K+ normal/low, no risk factors → Either rocuronium 1.2 mg/kg OR succinylcholine 1.5 mg/kg
↓
Proceed with intubation
↓
If ROSC achieved → Immediate sedation/analgesia

This approach prioritizes mortality reduction (optimizing intubation success without hemodynamic compromise from unnecessary sedatives) and quality of life (preventing awareness during paralysis post-ROSC) while acknowledging the unique physiology of both cardiac arrest and chronic kidney disease 1.